(4-MethylpyriMidin-2-yl)MethanaMine dihydrochloride
- $330 - $1532.96
- Product name: (4-MethylpyriMidin-2-yl)MethanaMine dihydrochloride
- CAS: 1390654-85-9
- MF: C6H11Cl2N3
- MW: 196.07764
- EINECS:
- MDL Number:MFCD22666535
- Synonyms:(4-MethylpyriMidin-2-yl)MethanaMine dihydrochloride;[(4-methyl-2-pyrimidinyl)methyl]amine dihydrochloride;2-Pyrimidinemethanamine, 4-methyl-, hydrochloride (1:2)
4 prices
Selected condition:
Brand
- Alichem
- Chemenu
- Crysdot
- TRC
Package
- 250mg
- 1g
- 5g
- ManufacturerAlichem
- Product number1390654859
- Product description(4-Methylpyrimidin-2-yl)methanaminedihydrochloride
- Packaging5g
- Price$1532.96
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM164677
- Product description(4-methylpyrimidin-2-yl)methanaminedihydrochloride 95%
- Packaging1g
- Price$489
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11267033
- Product description(4-Methylpyrimidin-2-yl)methanaminedihydrochloride 95+%
- Packaging1g
- Price$518
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberM325708
- Product description[(4-methyl-2-pyrimidinyl)methyl]aminedihydrochloride
- Packaging250mg
- Price$330
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Alichem | 1390654859 | (4-Methylpyrimidin-2-yl)methanaminedihydrochloride | 5g | $1532.96 | 2021-12-16 | Buy |
Chemenu | CM164677 | (4-methylpyrimidin-2-yl)methanaminedihydrochloride 95% | 1g | $489 | 2021-12-16 | Buy |
Crysdot | CD11267033 | (4-Methylpyrimidin-2-yl)methanaminedihydrochloride 95+% | 1g | $518 | 2021-12-16 | Buy |
TRC | M325708 | [(4-methyl-2-pyrimidinyl)methyl]aminedihydrochloride | 250mg | $330 | 2021-12-16 | Buy |
Properties
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|